TNAX Biopharma
A developer of pharmaceutical drugs intended to improve the quality of life of patients
About TNAX Biopharma
TNAX Biopharma Corporation, established in March 2018, is a privately held biopharmaceutical firm specializing in the discovery and development of novel antibody therapeutics. The company was co-founded by CEO Tak Mukohira and Chief Scientific Officer Dr. Akira Shibuya. Mr. Mukohira brings over 35 years of experience in business development and corporate strategy from his time at pharmaceutical companies like Mitsubishi Tanabe Pharma, including serving as President of its Boston-based venture capital arm. His background is complemented by Dr. Shibuya, a renowned immunologist and professor at the University of Tsukuba, who had 12 years of clinical experience before his research career. TNAX Biopharma was officially authorized as a startup originating from the University of Tsukuba, with which it conducts joint research and leverages exclusively licensed intellectual property.
The company's core focus is on developing pharmaceuticals that target the interaction between immunoreceptors and their ligands to treat intractable diseases with unmet medical needs. Its business model revolves around drug discovery innovation and forming strategic alliances for further development and commercialization. A key partnership is an exclusive worldwide licensing agreement with IMIDomics Inc., granting them the rights to develop and commercialize TNAX101A (renamed IMB1001). This agreement includes upfront payments, milestone achievements, and royalties, demonstrating a clear revenue generation strategy through licensing and collaboration.
TNAX Biopharma's pipeline addresses critical conditions such as acute kidney injury (AKI), acute ischemic stroke (AIS), and other immune-mediated inflammatory diseases. One of its leading candidates, TNAX103, is a humanized anti-CD300a monoclonal antibody designed to inhibit ischemia-reperfusion injury (IRI). This antibody functions as an efferocytosis promoter, enhancing the clearance of dead cells to suppress inflammation and prevent further tissue damage, which is a major trigger in conditions like cardiac surgery-associated AKI and stroke. Another key asset is IMB1001, a humanized antibody targeting CD226, which has shown potential to treat immune-mediated inflammatory diseases like ulcerative colitis by downregulating pro-inflammatory cytokines and exhibiting anti-fibrotic activity.
Source: Dealroom company dataNews
Open roles
TNAX Biopharma in the Tokyo ecosystem
The TNAX Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
JAFCO
Series A2 investors entered at this stage
Mitsubishi UFJ Capital
Nissay Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about TNAX Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TNAX Biopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

